banner
LightNews
ampath.bsky.social
Association for Molecular Pathology
@ampath.bsky.social
180 followers 86 following 210 posts
We provide global expertise in molecular testing that drives patient care. Visit www.amp.org to become a member or partner.
Posts Media Videos Starter Packs
ampath.bsky.social
Association for Molecular Pathology @ampath.bsky.social · 3h
📣Monday, Oct. 20, is the last day to save on registration for #AMPath2025!

🧐See the program: https://amp25.amp.org/program/amp-2025-program/

🥳Register: https://amp25.amp.org/registration/registration-rates-policies-and-target-audience/
ampath.bsky.social
Association for Molecular Pathology @ampath.bsky.social · 8h
Hear from #AMPath2025 plenary speaker Heidi Rehm, Ph.D., about the #molpath field's efforts to address challenges with identifying and reporting variants of uncertain significance (VUS) during germline genetic testing.

🔎 View details: https://amp25.amp.org/program/amp-2025-program/
1
ampath.bsky.social
Association for Molecular Pathology @ampath.bsky.social · 2d
Last week AMP staffers and President Jane Gibson were on Capitol Hill to express their concerns regarding the Patent Eligibility Restoration Act.

To learn more about AMP’s stance, visit:
https://www.amp.org/advocacy/take-action

(Pictured: Two AMP staffers alongside AMP President Jane Gibson)
Two AMP staffers and AMP President Jane Gibson on Capitol Hill.
1 1
ampath.bsky.social
Association for Molecular Pathology @ampath.bsky.social · 2d
Attend #AMP2025 for cutting-edge plenaries on the latest #molecular research, advances and opportunities. Hear from experts like Ola Landgren, W. Ian Lipkin, Takunda Matose, Heidi Rehm, Robin Coope and Malachi Griffith!

Learn more: https://amp25.amp.org/program/amp-2025-program/
Headshots of all six plenary lecturers alongside their institutional information and the titles of their talks.
ampath.bsky.social
Association for Molecular Pathology @ampath.bsky.social · 5d
At #AMP2025, Takunda Matose, Ph.D., will explore AI's role within molecular pathology and the ethical questions to consider.

🔗 More info here: https://amp25.amp.org/program/amp-2025-program/
1 1
ampath.bsky.social
Association for Molecular Pathology @ampath.bsky.social · 6d
📣Oct. 20 is the last day to save on #AMP2025 registration!

See the program: https://amp25.amp.org/program/amp-2025-program/

Register: https://amp25.amp.org/registration/registration-rates-policies-and-target-audience/
Graphic shows Boston skyline under AMP2025 Annual Meeting & Expo logo. The dates of the meeting are listed as November 11 to 15, and the location of the meeting is listed as Boston. At the bottom, it says, "Register now for the premier meeting for molecular professionals." Under that text is a link to the AMP2025 website (amp25.amp.org).
ampath.bsky.social
Association for Molecular Pathology @ampath.bsky.social · 6d
📣Today’s the day! Join us at 1 p.m. ET for a FREE webinar to learn more about the use of cell-free DNA from cerebrospinal fluid for diagnosis and molecular testing of brain tumors.

Register: educate.amp.org/loca...
Flyer advertising a new free webinar as part of the Association of Molecular Biology’s Emerging and Evolving Biomarkers series, titled “Cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) for diagnosis and molecular testing of brain tumors.” The webinar is scheduled for 1 p.m. Eastern on October 9. On the left is a close-up image of a strand of DNA. On the right is a photograph of Tejus A. Bale, the webinar speaker, and Pawel Mroz, the webinar moderator. At the bottom of the image, the level of instruction for the webinar is labeled as intermediate and CME/CMLE credit of 1.0 is offered.
ampath.bsky.social
Association for Molecular Pathology @ampath.bsky.social · 7d
On Oct. 16 we will host a FREE webinar on next-gen sequencing for clonality & immune repertoire analysis.
It will address why TCR diversity matters, compare DNA testing methods & explore a key genetic marker in CLL.
#/registrationistration" class="hover:underline text-blue-600 dark:text-sky-400" target="_blank" rel="noopener">https://us06web.zoom.us/webinar/register/WN_8g4hi-I8QaqfTMCGiqrrbQ#/registration
Announcement of the AMP online corporate workshop "NGS applications: Assessing clonality and diversity" on October 16 at 1 p.m. Eastern. Headshots of the two speakers, Rebecca Ramesh and Jeremiah X. Karrs, are featured.
ampath.bsky.social
Association for Molecular Pathology @ampath.bsky.social · 8d
Join W. Ian Lipkin, M.D., at #AMPath2025 for the Nov. 13 plenary lecture "Small Game Hunting," which explores historic and current methods for infectious disease diagnosis, surveillance and discovery.

View program details 👉🏽 https://amp25.amp.org/program/amp-2025-program/
1 1 1
ampath.bsky.social
Association for Molecular Pathology @ampath.bsky.social · 12d
⏯️The Emerging and Evolving Biomarkers: Methylation Profiling webinar is now available on YouTube!

Learn how DNA methylation profiling can be used to refine tumor classification schemes & as a clinical diagnostic for molecular tumor classification.

youtu.be/Sb3FaJu8hbg
Text on the left reads: New on our YouTube channel: Emerging and Evolving Biomarkers: Methylation Profiling with a link to AMP's YouTube page. To the right is the introductory slide from the webinar.
ampath.bsky.social
Association for Molecular Pathology @ampath.bsky.social · 13d
Curious about the taxonomy of multiple myeloma?

Attend #AMPath2025 for insights from Ola Landgren, M.D., Ph.D., on genomic classification and prognosis in MM and the future for genetic profiling in precision medicine for it: amp25.amp.org/progra...
Headshot of Ola Landgren from University of Miami Miller School of Medicine alongside the title of his AMP 2025 plenary talk, "Genomic Classification and Individualized Prognosis in Multiple Myeloma"
2
ampath.bsky.social
Association for Molecular Pathology @ampath.bsky.social · 13d
Reminder to check out our latest CAP Today case report to learn about why a discrepancy between a negative molecular testing result in a tumor and a positive genetic variation presence may occur.

To read this and other case reports, visit www.amp.org/clinical...
At top, Cap Today header. Underneath, the article title, "Germline variant not present in tumor?"
Reposted by Association for Molecular Pathology
jmdiagn.bsky.social
The Journal of Molecular Diagnostics @jmdiagn.bsky.social · 14d
Read the closing editorial for our #JMDSilver celebration, from Editor in Chief Ron Przygodzki: Celebrating 25 Years of Innovation with a Tribute to Our Contributors and the Future of Molecular Diagnostics

Full text: https://www.jmdjournal.org/article/S1525-1578(25)00192-8/fulltext
1
Reposted by Association for Molecular Pathology
jmdiagn.bsky.social
The Journal of Molecular Diagnostics @jmdiagn.bsky.social · 14d
New month, new #LegacyContent! The full October 2024 issue of @jmdiagn.bsky.social is now free in the #OpenArchive.

Full issue: https://www.jmdjournal.org/issue/S1525-1578(23)X0013-0
2 1
ampath.bsky.social
Association for Molecular Pathology @ampath.bsky.social · 14d
🧠Join us on Oct. 9 at 1 p.m. ET for a FREE webinar to learn about how cfDNA from CSF can be used for diagnosis and molecular testing of brain tumors.

CME/CMLE credit is available!

Register here: educate.amp.org/loca...
Flyer advertising a new free webinar as part of the Association of Molecular Biology’s Emerging and Evolving Biomarkers series, titled “Cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) for diagnosis and molecular testing of brain tumors.” The webinar is scheduled for 1 p.m. Eastern on October 9. On the left is a close-up image of a strand of DNA. On the right is a photograph of Tejus A. Bale, the webinar speaker, and Pawel Mroz, the webinar moderator. At the bottom of the image, the level of instruction for the webinar is labeled as intermediate and CME/CMLE credit of 1.0 is offered.
1
ampath.bsky.social
Association for Molecular Pathology @ampath.bsky.social · 15d
Interested in looking at how new DNA sequencing technologies are being used to study immune cells and detect cancer? Attend our FREE Oct. 16 webinar, "NGS applications: Assessing clonality and diversity"!

Register here: us06web.zoom.us/webi...
Announcement of the AMP online corporate workshop "NGS applications: Assessing clonality and diversity" on October 16 at 1 p.m. Eastern. Headshots of the two speakers, Rebecca Ramesh and Jeremiah X. Karrs, are featured.
1
Reposted by Association for Molecular Pathology
jmdiagn.bsky.social
The Journal of Molecular Diagnostics @jmdiagn.bsky.social · 26d
Cost-effectiveness Analysis of Comprehensive Genomic Profiling in Patients with Advanced Non-small Cell Lung Cancer Using Real-world Data.

Full text: https://www.jmdjournal.org/article/S1525-1578(25)00165-5/fulltext
Cost-effectiveness Analysis of Comprehensive Genomic Profiling in Patients with Advanced Non-small Cell Lung Cancer Using Real-world Data
Cancer treatment costs pose a significant global economic burden. By facilitating treatment plans tailored to the genomic profile of patients’ cancer, genomic testing has the potential to reduce healthcare costs. Using real-world evidence, this study compared the cost-effectiveness of comprehensive genomic profiling (CGP) versus small panel (SP) testing in patients with advanced non-small cell lung cancer (aNSCLC) in the US and Germany. A partitioned survival model was developed to estimate t...
www.jmdjournal.org
1
ampath.bsky.social
Association for Molecular Pathology @ampath.bsky.social · 20d
Curious about cfDNA? Join us Oct. 9 to learn about:

✅The origin of cfDNA & biological factors that may influence detection
✅Collection & extraction techniques for cfDNA
✅How molecular testing of cfDNA from CF is being used in clinical care

Register: educate.amp.org/loca...
Flyer advertising a new free webinar as part of the Association of Molecular Biology’s Emerging and Evolving Biomarkers series, titled “Cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) for diagnosis and molecular testing of brain tumors.” The webinar is scheduled for 1 p.m. Eastern on October 9. On the left is a close-up image of a strand of DNA. On the right is a photograph of Tejus A. Bale, the webinar speaker, and Pawel Mroz, the webinar moderator. At the bottom of the image, the level of instruction for the webinar is labeled as intermediate and CME/CMLE credit of 1.0 is offered.
ampath.bsky.social
Association for Molecular Pathology @ampath.bsky.social · 21d
Join us at #AMP2025 to hear from Malachi Griffith, Ph.D., on using RNA sequencing for splice variant discovery and somatic variant prioritization in precision oncology.

🧬 View the full scientific program for details: amp25.amp.org/program/amp-...
Headshot of Malachi Griffith from Washington University in St. Louis School of Medicine alongside the title of his AMP 2025 plenary talk, "Leveraging RNA Sequencing for Splice Variant Discovery and Somatic Variant Prioritization in Precision Oncology."
Reposted by Association for Molecular Pathology
jmdiagn.bsky.social
The Journal of Molecular Diagnostics @jmdiagn.bsky.social · 27d
#LegacyContent: Assessing the risk stratification of breast cancer polygenic risk scores in a Brazilian cohort. Authors from @brynmawrcollege.bsky.social

Free in the #OpenArchive: https://www.jmdjournal.org/article/S1525-1578(24)00150-8/fulltext
1
ampath.bsky.social
Association for Molecular Pathology @ampath.bsky.social · 23d
A new case report in CAP Today reminds us that “it is imperative to consider that a negative molecular testing result does not equate with absence of variation.”

Learn how this type of discrepancy is possible in testing a tumor in our latest case report: www.amp.org/clinical...
At top, Cap Today header. Underneath, the article title, "Germline variant not present in tumor?"
ampath.bsky.social
Association for Molecular Pathology @ampath.bsky.social · 26d
Learn about AMP's case against the FDA: www.amp.org/advocacy/amp...
AMP v FDA
Learn about the impact of the FDA's final rule on laboratory-developed tests.
www.amp.org
ampath.bsky.social
Association for Molecular Pathology @ampath.bsky.social · 26d
It's official: FDA rescinds final rule regulating laboratory-developed testing procedures as medical devices. www.medtechdive.com/news/FDA-res...
FDA rescinds LDT final rule
Regulation of lab developed tests returns to its status before the agency attempted to expand its jurisdiction and industry groups sued to stop it.
www.medtechdive.com
1
ampath.bsky.social
Association for Molecular Pathology @ampath.bsky.social · 26d
🥳 Before National Postdoc Appreciation Week ends, we want to remind all postdocs interested in joining AMP that associate membership for postdocs is free for the duration of your training (up to 7 years): www.amp.org/membersh...

#NPAW2025 #NPAW #postdocs
Image of woman in scientific lab. Text to her left reads "Become an AMP member!" with a link to AMP's membership website, www.amp.org/membership
Reposted by Association for Molecular Pathology
jmdiagn.bsky.social
The Journal of Molecular Diagnostics @jmdiagn.bsky.social · 28d
Development of a Multiplex Real-Time PCR Assay for the Rapid Detection of the Asian-Type DEL.

#OpenAccess text: https://www.jmdjournal.org/article/S1525-1578(25)00161-8/fulltext
Development of a Multiplex Real-Time PCR Assay for the Rapid Detection of the Asian-Type DEL
Asian-type DEL (RHD, c.1227G>A) is relatively prevalent in East Asians and is essential to detect in serologic rhesus (Rh) D-negative individuals. Despite the recognized importance of identifying Asian-type DEL, traditional detection methods, such as adsorption-elution and Sanger sequencing, are complex and time-consuming. A reliable method is required for the rapid and precise detection of Asian-type DEL. A novel multiplex real-time PCR assay using allele-specific TaqMan hydrolysis probes wa...
www.jmdjournal.org
1